Multi-marker urine test to detect bladder cancer coming back
Multiplex and multi-omic diagnostic test for bladder cancer recurrence
This project offers a urine test that looks for multiple cancer markers to help people treated for bladder cancer spot recurrence sooner.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Early Is Good INC. NIH-funded |
| Lab location | 1 site (Muncie, United States) |
| Project ID | NIH-11195583 on NIH RePORTER |
What this research studies
You would provide a urine sample that the company’s BCDx test analyzes using advanced nanotechnology to read twelve different biomarkers at once. The test measures several types of markers (proteins, microRNAs, messenger RNAs, and long noncoding RNAs) to create a multi-omic picture instead of relying on a single signal. Early lab and feasibility work showed very high sensitivity and the ability to separate healthy urine from cancerous samples and to distinguish low- from high-grade tumors. This project aims to further validate those results so the test could be used during routine surveillance for recurrence.
Who could benefit from this research
Good fit: Ideal candidates are people who have been treated for bladder cancer and are under surveillance for recurrence who can provide urine samples.
Not a fit: People without a history of bladder cancer, those with cancers of other organs, or patients unable to provide urine samples may not benefit from this project.
Why it matters
Potential benefit: If successful, the test could let patients check for recurrence with a simple urine sample and reduce the need for frequent invasive cystoscopies.
How similar studies have performed: Existing single-marker urine tests have had limited accuracy, and while other multi-marker approaches are emerging, this specific multi-omic, multiplex nanotechnology approach is relatively new with only early feasibility data so far.
Where this research is happening
Muncie, United States
- Early Is Good INC. — Muncie, United States (Active)
Researchers
- Principal investigator: Liyanage, Thakshila — Early Is Good INC.
- Study coordinator: Liyanage, Thakshila
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.